Changes in mitral regurgitation after transcatheter aortic valve implantation
Open Access
- 30 June 2009
- journal article
- valvular and-structural-heart-diseases
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 75 (1), 43-49
- https://doi.org/10.1002/ccd.22197
Abstract
Objectives: To assess the acute and intermediate changes in mitral regurgitation (MR) severity after transcatheter aortic valve implantation (TAVI) with the CoreValve Revalving SystemTM (CRS). Background: Following surgical aortic valve replacement, improvement in MR is reported in 27–82% of the patients. The changes in MR severity following CRS implantation are unknown. Methods: Transthoracic echocardiography was performed in 79 consecutive patients before and after treatment, and at the first outpatient visit. Left ventricular dimensions and ejection fraction (LVEF), left atrial (LA) size, and aortic gradient were measured. MR was assessed by color flow mapping and was graded as none, mild, moderate, or severe. It was defined as organic or functional. The depth of CRS implantation was measured by angiography. Results: Post‐treatment, the mean gradient decreased from 48 ± 16 mm Hg to 9 ± 5 mm Hg (P < 0.0001). There was no significant change in the left ventricular dimensions, LA size, and LVEF. MR pretreatment was mild, moderate, or severe in 57%, 18%, and 1% of the patients, respectively. It was defined as organic in 27 patients (36%) and functional in 27 patients (36%). The degree of MR remained unchanged in 61% of the patients, improved in 17%, and worsened in 22%. MR improvement was associated with a lower baseline LVEF (P = 0.02). There was no association between the changes in MR severity and the depth of CRS implantation. Conclusions: Most patients who underwent TAVI had some degree of MR. Overall there was no change in the degree of MR post‐treatment. Patients in whom MR improved had a lower LVEF at baseline.Keywords
This publication has 22 references indexed in Scilit:
- Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) CoreValve ReValving System: results from the multicentre, expanded evaluation registry 1-year following CE mark approvalEuroIntervention, 2008
- Incidence, associated factors and evolution of non-severe functional mitral regurgitation in patients with severe aortic stenosis undergoing aortic valve replacementEuropean Journal of Cardio-Thoracic Surgery, 2008
- Guidelines on the management of valvular heart disease: replyEuropean Heart Journal, 2007
- Natural History and Predictors of Outcome in Patients With Concomitant Functional Mitral Regurgitation at the Time of Aortic Valve ReplacementCirculation, 2006
- Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of CardiologyEuropean Heart Journal, 2006
- Treatment of Calcific Aortic Stenosis With the Percutaneous Heart Valve: Mid-Term Follow-Up From the Initial Feasibility Studies: The French ExperienceJournal of the American College of Cardiology, 2006
- Does Functional Mitral Regurgitation Improve with Isolated Aortic Valve Replacement?Journal of Cardiac Surgery, 2004
- Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiographyJournal of the American Society of Echocardiography, 2003
- Lack of improvement in coexisting mitral regurgitation after relief of valvular aortic stenosisThe American Journal of Cardiology, 1990
- Effect of aortic valve replacement for aortic stenosis on severity of mitral regurgitationThe American Journal of Cardiology, 1990